Publications
| Title | Abstract | Year(sorted descending) Filter | PMID Filter |
|---|
| mitochondrial dysfunction induced by n-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide is required for cell death of trypanosoma cruzi. | chagas' disease is caused by the protozoan trypanosoma cruzi and affects thousands of people worldwide. the available treatments are unsatisfactory, and new drugs must be developed. our group recently reported the trypanocidal activity of the synthetic compound n-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide (c4), but the mechanism of action of this compound was unclear. | 2015 | 26086449 |
| bottlenecks in domestic animal populations can facilitate the emergence of trypanosoma cruzi, the aetiological agent of chagas disease. | faeces-mediated transmission of trypanosoma cruzi (the aetiological agent of chagas disease) by triatomine insects is extremely inefficient. still, the parasite emerges frequently, and has infected millions of people and domestic animals. we synthesize here the results of field and laboratory studies of t. cruzi transmission conducted in and around arequipa, peru. we document the repeated occurrence of large colonies of triatomine bugs (more than 1000) with very high infection prevalence (more t ... | 2015 | 26085582 |
| studies of genotoxicity and mutagenicity of nitroimidazoles: demystifying this critical relationship with the nitro group. | nitroimidazoles exhibit high microbicidal activity, but mutagenic, genotoxic and cytotoxic properties have been attributed to the presence of the nitro group. however, we synthesised nitroimidazoles with activity against the trypomastigotes of trypanosoma cruzi, but that were not genotoxic. herein, nitroimidazoles (11-19) bearing different substituent groups were investigated for their potential induction of genotoxicity (comet assay) and mutagenicity (salmonella/microsome assay) and the correla ... | 2015 | 26018452 |
| limited ability of posaconazole to cure both acute and chronic trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. | the antifungal drug posaconazole has shown significant activity against trypanosoma cruzi in vitro and in experimental murine models. despite this, in a recent clinical trial it displayed limited curative potential. drug testing is problematic in experimental chagas disease because of difficulties in demonstrating sterile cure, particularly during the chronic stage of infection when parasite burden is extremely low and tissue distribution is ill defined. to better assess posaconazole efficacy ag ... | 2015 | 26014936 |
| bimodal distribution of trypanosoma cruzi antibody levels in blood donors from a highly endemic area of argentina: what is the significance of low-reactive samples? | low-level seroreactive donor samples that are inconsistently detected by different trypanosoma cruzi immunoassays are common, but the population distribution has not been reported in an endemic region. the objective was to understand the distribution of low-level reactive samples using highly sensitive immunoassays and the relationship with epidemiologic evidence of exposure to t. cruzi. | 2015 | 26014113 |
| are members of the triatoma brasiliensis (hemiptera, reduviidae) species complex able to alter the biology and virulence of a trypanosoma cruzi strain? | trypanosoma cruzi is the causative agent of chagas disease, transmitted to humans and mammals by blood-sucking hemipteran insects belonging to the triatominae subfamily. the two main genotypes of t. cruzi (tci and tcii) differ in many characteristics concerning their genetic profile. despite the extensive literature on vectors and the etiologic agent, several interactive aspects between these two elements of chagas disease are still waiting to be further clarified. here, biological and histologi ... | 2015 | 26013138 |
| insecticide resistance in vector chagas disease: evolution, mechanisms and management. | chagas disease is a chronic parasitic infection restricted to america. the disease is caused by the protozoa trypanosoma cruzi, which is transmitted to human through the feces of infected triatomine insects. because no treatment is available for the chronic forms of the disease, vector chemical control represents the best way to reduce the incidence of the disease. chemical control has been based principally on spraying dwellings with insecticide formulations and led to the reduction of triatomi ... | 2015 | 26003952 |
| arrhythmias in chagasic cardiomyopathy. | chagas disease, a chronic parasitosis caused by the protozoa trypanosoma cruzi, is an increasing worldwide problem because of the number of cases in endemic areas and the migration of infected individuals to more developed regions. chagas disease affects the heart through cardiac parasympathetic neuronal depopulation, immune-mediated myocardial injury, parasite persistence in cardiac tissue with secondary antigenic stimulation, and coronary microvascular abnormalities causing myocardial ischemia ... | 2015 | 26002390 |
| prevalence and transmission of trypanosoma cruzi in people of rural communities of the high jungle of northern peru. | vector-borne transmission of trypanosoma cruzi is seen exclusively in the americas where an estimated 8 million people are infected with the parasite. significant research in southern peru has been conducted to understand t. cruzi infection and vector control, however, much less is known about the burden of infection and epidemiology in northern peru. | 2015 | 26000770 |
| cruzipain: an update on its potential as chemotherapy target against the human pathogen trypanosoma cruzi. | chagas' disease is one of the most impactful and prevalent neglected tropical diseases in the americas, specially affecting the poor and underdeveloped areas in latin america. aggravating this scenario, the medicines used in the current chemotherapy are old, toxic and present a low efficacy to treat the chronic stage of this disease. in addition, resistant strains of trypanosoma cruzi, the etiological agent, are frequently reported. so, there is an imperative requirement for novel chemotherapeut ... | 2015 | 25994861 |
| the epidemiology, clinical manifestations, and management of chagas heart disease. | chagas disease results from infection by the protozoan parasite trypanosoma cruzi and is endemic in latin america. t cruzi is most commonly transmitted through the feces of an infected triatomine, but can also be congenital, via contaminated blood transfusion or through direct oral contact. in the acute phase, the disease can cause cardiac derangements such as myocarditis, conduction system abnormalities, and/or pericarditis. if left untreated, the disease advances to the chronic phase. up to on ... | 2015 | 25993972 |
| modulation of trypanosoma cruzi-specific t-cell responses after chemotherapy for chronic chagas disease. | the aim of this review is to describe the contributions of the knowledge of t-cell responses to the understanding of the physiopathology and the responsiveness to etiological treatment during the chronic phase of chagas disease. t-helper (th)1 and interleukin (il)-10 trypanosoma cruzi-specific t-cells have been linked to the asymptomatic phase or to severe clinical forms of the disease, respectively or vice versa, depending on the t. cruzi antigen source, the patient's location and the performed ... | 2015 | 25993507 |
| congenital transmission of trypanosoma cruzi in central brazil. a study of 1,211 individuals born to infected mothers. | transmission of trypanosoma cruzi during pregnancy is estimated to occur in less than 20% of infected mothers; however, the etiopathogenesis is not completely understood. the centre for studies on chagas disease provides confirmation of t. cruzi infection for individuals living in central brazil. in this retrospective hospital-based study, all requests for diagnosis of t. cruzi infection in individuals less than 21 years old from 1994-2014 were searched. we end with 1,211 individuals and their r ... | 2015 | 25993506 |
| atlas of mexican triatominae (reduviidae: hemiptera) and vector transmission of chagas disease. | chagas disease is one of the most important yet neglected parasitic diseases in mexico and is transmitted by triatominae. nineteen of the 31 mexican triatomine species have been consistently found to invade human houses and all have been found to be naturally infected with trypanosoma cruzi. the present paper aims to produce a state-of-knowledge atlas of mexican triatomines and analyse their geographic associations with t. cruzi, human demographics and landscape modification. ecological niche mo ... | 2015 | 25993505 |
| integrated control of chagas disease for its elimination as public health problem--a review. | chagas disease or american trypanosomiasis is, together with geohelminths, the neglected disease that causes more loss of years of healthy life due to disability in latin america. chagas disease, as determined by the factors and determinants, shows that different contexts require different actions, preventing new cases or reducing the burden of disease. control strategies must combine two general courses of action including prevention of transmission to prevent the occurrence of new cases (these ... | 2015 | 25993503 |
| multiplex real-time pcr assay using taqman probes for the identification of trypanosoma cruzi dtus in biological and clinical samples. | trypanosoma cruzi has been classified into six discrete typing units (dtus), designated as tci-tcvi. in order to effectively use this standardized nomenclature, a reproducible genotyping strategy is imperative. several typing schemes have been developed with variable levels of complexity, selectivity and analytical sensitivity. most of them can be only applied to cultured stocks. in this context, we aimed to develop a multiplex real-time pcr method to identify the six t. cruzi dtus using taqman ... | 2015 | 25993316 |
| health-related quality of life in patients with chagas disease: a review of the evidence. | chagas disease (chd), a neglected tropical disease caused by infection with the parasite trypanosoma cruzi (t. cruzi), remains a serious public health issue in latin america and is an emerging disease in several non-endemic countries, where knowledge of the condition and experience with its clinical management are limited. regionally, the disease is the major cause of disability secondary to tropical diseases in young adults. health-related quality of life (hrqol) impairment is common in patient ... | 2015 | 25992924 |
| eukaryotic translation elongation factor-1 alpha is associated with a specific subset of mrnas in trypanosoma cruzi. | regulation of gene expression in trypanosomatids is mainly posttranscriptional. tight regulation of mrna stability and access to polysomes allows trypanosoma cruzi to adapt to different environmental conditions during its life cycle. posttranscriptional regulation requires association between mrnas and specific proteins to form mrnp complexes. proteins that lack a canonical rna-binding domain, such as eukaryotic elongation factor-1α (ef-1α), may also associate with mrnps. ef-1α is conserved in m ... | 2015 | 25986694 |
| potential sexual transmission of trypanosoma cruzi in mice. | infection with the protozoan parasite trypanosoma cruzi, the etiologic agent of human chagas disease, results in life-long infection. infective trypomastigotes circulate in the bloodstream and have the capacity to infect any cell type, including reproductive tissue. this study sought to assess the potential for sexual transmission of t. cruzi in an experimental mouse model. the conditions used in this study, in which acutely infected males and immunosuppressing the females, created a worst-case ... | 2015 | 25982870 |
| simvastatin and benznidazole-mediated prevention of trypanosoma cruzi-induced endothelial activation: role of 15-epi-lipoxin a4 in the action of simvastatin. | trypanosoma cruzi is the causal agent of chagas disease that is endemic in latin american, afflicting more than ten million people approximately. this disease has two phases, acute and chronic. the acute phase is often asymptomatic, but with time it progresses to the chronic phase, affecting the heart and gastrointestinal tract and can be lethal. chronic chagas cardiomyopathy involves an inflammatory vasculopathy. endothelial activation during chagas disease entails the expression of cell adhesi ... | 2015 | 25978361 |
| first quantum mechanics/molecular mechanics studies of the inhibition mechanism of cruzain by peptidyl halomethyl ketones. | cruzain is a primary cysteine protease expressed by the protozoan parasite trypanosoma cruzi during chagas disease infection, and thus, the development of inhibitors of this protein is a promising target for designing an effective therapy against the disease. in this paper, the mechanism of inhibition of cruzain by two different irreversible peptidyl halomethyl ketones (phk) inhibitors has been studied by means of hybrid quantum mechanics/molecular mechanics-molecular dynamics (md) simulations t ... | 2015 | 25965914 |
| rab32 is essential for maintaining functional acidocalcisomes, and for growth and infectivity of trypanosoma cruzi. | the contractile vacuole complex (cvc) of trypanosoma cruzi, the etiologic agent of chagas disease, collects and expels excess water as a mechanism of regulatory volume decrease after hyposmotic stress; it also has a role in cell shrinking after hyperosmotic stress. here, we report that, in addition to its role in osmoregulation, the cvc of t. cruzi has a role in the biogenesis of acidocalcisomes. expression of dominant-negative mutants of the cvc-located small gtpase rab32 (tcclb.506289.80) resu ... | 2015 | 25964650 |
| markers for the population genetics studies of triatoma sordida (hemiptera: reduviidae). | triatoma sordida, a vector of trypanosoma cruzi, is native of brazil, bolivia, paraguay, argentina, and uruguay, and occurs primarily in peridomiciles. currently, it is the species most frequently captured by the chagas disease control program in brazil. for this reason, population genetic studies attract great interest, as they can provide further information about the dispersal and household invasion processes of this species. in the absence of suitable markers, the objective of this study was ... | 2015 | 25963633 |
| the potential of canine sentinels for reemerging trypanosoma cruzi transmission. | chagas disease, a vector-borne disease transmitted by triatomine bugs and caused by the parasite trypanosoma cruzi, affects millions of people in the americas. in arequipa, peru, indoor residual insecticide spraying campaigns are routinely conducted to eliminate triatoma infestans, the only vector in this area. following insecticide spraying, there is risk of vector return and reinitiation of parasite transmission. dogs are important reservoirs of t. cruzi and may play a role in reinitiating tra ... | 2015 | 25962956 |
| pharmacophore modeling for anti-chagas drug design using the fragment molecular orbital method. | chagas disease, caused by the parasite trypanosoma cruzi, is a neglected tropical disease that causes severe human health problems. to develop a new chemotherapeutic agent for the treatment of chagas disease, we predicted a pharmacophore model for t. cruzi dihydroorotate dehydrogenase (tcdhodh) by fragment molecular orbital (fmo) calculation for orotate, oxonate, and 43 orotate derivatives. | 2015 | 25961853 |
| cox-2 rs20417 polymorphism is associated with stroke and white matter disease. | to investigate the effect of cox-2 polymorphism and its product, prostaglandin e2 (pge2), on stroke risk in an endemic area for chagas disease. in a separate cohort, to investigate the effect of cox-2 polymorphisms on the total burden of cerebral white matter disease. | 2015 | 25957909 |
| a two-component dna-prime/protein-boost vaccination strategy for eliciting long-term, protective t cell immunity against trypanosoma cruzi. | in this study, we evaluated the long-term efficacy of a two-component subunit vaccine against trypanosoma cruzi infection. c57bl/6 mice were immunized with tcg2/tcg4 vaccine delivered by a dna-prime/protein-boost (d/p) approach and challenged with t. cruzi at 120 or 180 days post-vaccination (dpv). we examined whether vaccine-primed t cell immunity was capable of rapid expansion and intercepting the infecting t. cruzi. our data showed that d/p vaccine elicited cd4+ (30-38%) and cd8+ (22-42%) t c ... | 2015 | 25951312 |
| negativation of trypanosoma cruzi pcr within six months after treatment of a child with nifurtimox. | 2015 | 25951170 | |
| factors associated with the occurrence of triatoma sordida (hemiptera: reduviidae) in rural localities of central-west brazil. | this study estimates the factors of artificial environments (houses and peridomestic areas) associated with triatoma sordida occurrence. manual searches for triatomines were performed in 136 domiciliary units (dus) in two rural localities of central-west brazil. for each du, 32 structural, 23 biotic and 28 management variables were obtained. multiple logistic regression analysis was performed in order to identify statistically significant variables associated with occurrence of t. sordida in the ... | 2015 | 25946242 |
| role of cyclooxygenase-2 in trypanosoma cruzi survival in the early stages of parasite host-cell interaction. | chagas disease, caused by the intracellular protozoan trypanosoma cruzi, is a serious health problem in latin america. during this parasitic infection, the heart is one of the major organs affected. the pathogenesis of tissue remodelling, particularly regarding cardiomyocyte behaviour after parasite infection and the molecular mechanisms that occur immediately following parasite entry into host cells are not yet completely understood. when cells are infected with t. cruzi, they develop an inflam ... | 2015 | 25946241 |
| reaching for the holy grail: insights from infection/cure models on the prospects for vaccines for trypanosoma cruzi infection. | prevention of trypanosoma cruzi infection in mammals likely depends on either prevention of the invading trypomastigotes from infecting host cells or the rapid recognition and killing of the newly infected cells by t. cruzi-specific t cells. we show here that multiple rounds of infection and cure (by drug therapy) fails to protect mice from reinfection, despite the generation of potent t cell responses. this disappointing result is similar to that obtained with many other vaccine protocols used ... | 2015 | 25946159 |
| retrospective distribution of trypanosoma cruzi i genotypes in colombia. | trypanosoma cruzi is the aetiological agent of chagas disease, which affects approximately eight million people in the americas. this parasite exhibits genetic variability, with at least six discrete typing units broadly distributed in the american continent. t. cruzi i (tci) shows remarkable genetic diversity; a genotype linked to human infections and a domestic cycle of transmission have recently been identified, hence, this strain was named tcidom. the aim of this work was to describe the spa ... | 2015 | 25946157 |
| infection with trypanosoma cruzi tcii and tci in free-ranging population of lion tamarins (leontopithecus spp): an 11-year follow-up. | here, we present a review of the dataset resulting from the 11-years follow-up of trypanosoma cruzi infection in free-ranging populations of leontopithecus rosalia (golden lion tamarin) and leontopithecus chrysomelas (golden-headed lion tamarin) from distinct forest fragments in atlantic coastal rainforest. additionally, we present new data regarding t. cruzi infection of small mammals (rodents and marsupials) that live in the same areas as golden lion tamarins and characterisation at discrete t ... | 2015 | 25946156 |
| update on oral chagas disease outbreaks in venezuela: epidemiological, clinical and diagnostic approaches. | orally transmitted chagas disease has become a matter of concern due to outbreaks reported in four latin american countries. although several mechanisms for orally transmitted chagas disease transmission have been proposed, food and beverages contaminated with whole infected triatomines or their faeces, which contain metacyclic trypomastigotes of trypanosoma cruzi, seems to be the primary vehicle. in 2007, the first recognised outbreak of orally transmitted chagas disease occurred in venezuela a ... | 2015 | 25946155 |
| immunological response to re-infections with clones of the colombian strain of trypanosoma cruzi with different degrees of virulence: influence on pathological features during chronic infection in mice. | re-infections with trypanosoma cruzi are an aggravating factor for chagas disease morbidity. the colombian strain of t. cruzi represents multiclonal populations formed by clonally propagating organisms with different tropisms and degrees of virulence. in the present study, the influence of successive inoculations with clones of the colombian strain, exhibiting different degrees of virulence, on chronic myocarditis and the humoral and cellular immune responses (col-c1 high virulence, col-c8 mediu ... | 2015 | 25946153 |
| a novel abcg-like transporter of trypanosoma cruzi is involved in natural resistance to benznidazole. | benznidazole (bz) is one of the two drugs used for chagas disease treatment. nevertheless therapeutic failures of bz have been reported, which were mostly attributed to variable drug susceptibility among trypanosoma cruzi strains. atp-binding cassette (abc) transporters are involved in a variety of translocation processes and some members have been implicated in drug resistance. here we report the characterisation of the first t. cruzi abcg transporter gene, named tcabcg1, which is over-expresse ... | 2015 | 25946152 |
| biomarkers of therapeutic responses in chronic chagas disease: state of the art and future perspectives. | the definition of a biomarker provided by the world health organization is any substance, structure, or process that can be measured in the body, or its products and influence, or predict the incidence or outcome of disease. currently, the lack of prognosis and progression markers for chronic chagas disease has posed limitations for testing new drugs to treat this neglected disease. several molecules and techniques to detect biomarkers in trypanosoma cruzi-infected patients have been proposed to ... | 2015 | 25946151 |
| impact of benznidazole on infection course in mice experimentally infected with trypanosoma cruzi i, ii, and iv. | american trypanosomiasis is an emerging zoonosis in the brazilian amazon. studies on benznidazole (bz) chemotherapy with trypanosoma cruzi from this region have great relevance, given the different discrete typing units (dtus) that infect humans in the amazon and other regions of brazil. we performed a parasitological, histopathological, and molecular analysis of mice inoculated with strains of t. cruzi i, ii, and iv that were bz-treated during the acute phase of infection. groups of swiss mice ... | 2015 | 25940197 |
| cruzipain activates latent tgf-β from host cells during t. cruzi invasion. | several studies indicate that the activity of cruzipain, the main lysosomal cysteine peptidase of trypanosoma cruzi, contributes to parasite infectivity. in addition, the parasitic invasion process of mammalian host cells is described to be dependent on the activation of the host tgf-β signaling pathway by t. cruzi. here, we tested the hypothesis that cruzipain could be an important activator of latent tgf-β and thereby trigger tgf-β-mediated events crucial for the development of chagas disease. ... | 2015 | 25938232 |
| trypanosoma cruzi burden, genotypes, and clinical evaluation of chilean patients with chronic chagas cardiopathy. | there are currently no biomarkers to assess which patients with chronic indeterminate chagas disease will develop heart disease and which will spend their entire life in this state. we hypothetize that the parasite burden and trypanosoma cruzi genotypes are related to the presence of heart disease in patients with chagas disease. this study is aimed to investigate the parasite burden and t. cruzi genotypes in chagasic cardiopaths versus chagasic individuals without cardiac involvement according ... | 2015 | 25935204 |
| control of rural house infestation by triatoma infestans in the bolivian chaco using a microencapsulated insecticide formulation. | triatoma infestans, the main vector of trypanosoma cruzi (causative agent of chagas disease) has been successfully eliminated over much of its original geographic distribution over the southern cone countries of south america. however, populations of the species are still infesting houses of rural communities of the gran chaco region of argentina and bolivia. this study reports for the first time a large-scale effect of a vector control intervention using a microencapsulated formulation of organ ... | 2015 | 25928071 |
| chagas disease drug discovery: toward a new era. | american trypanosomiasis, or chagas disease, is the result of infection by the trypanosoma cruzi parasite. endemic in latin america where it is the major cause of death from cardiomyopathy, the impact of the disease is reaching global proportions through migrating populations. new drugs that are safe, efficacious, low cost, and adapted to the field are critically needed. over the past five years, there has been increased interest in the disease and a surge in activities within various organizati ... | 2015 | 25245987 |
| transferability of trypanosoma cruzi from mixed human host infection to triatoma infestans and from insects to axenic culture. | the etiologic agent of chagas disease is trypanosoma cruzi, a protozoan whose life cycle involves obligatory passage through vertebrate and invertebrate hosts in a series of stages. the aim of this study was to explore the transferability of mixed discrete typing units (dtus) of t. cruzi present in chronic chagasic patients when passed through an invertebrate host during xenodiagnosis (xd) and then when transferred to axenic cultures to obtain t. cruzi isolates. dtus of t. cruzi present in these ... | 2015 | 25240699 |
| a new experimental model for assessing drug efficacy against trypanosoma cruzi infection based on highly sensitive in vivo imaging. | the protozoan trypanosoma cruzi is the causative agent of chagas disease, one of the world's major neglected infections. although development of improved antiparasitic drugs is considered a priority, there have been no significant treatment advances in the past 40 years. factors that have limited progress include an incomplete understanding of pathogenesis, tissue tropism, and disease progression. in addition, in vivo models, which allow parasite burdens to be tracked throughout the chronic stag ... | 2015 | 25296657 |
| interactions of human galectins with trypanosoma cruzi: binding profile correlate with genetic clustering of lineages. | we report here the specific interaction between several members of the human galectin family with the three developmental stages of several genetic lineages of the protozoan parasite trypanosoma cruzi. we provide data of specific and differential binding of human galectin (gal)-1, -3, -4, -7 and -8 to 14 strains of t. cruzi that belong to the six genetic lineages representing the genetic diversity of the parasite. it is shown that galectins preferentially bind forms present in the host, trypomas ... | 2015 | 25267603 |
| profiling transition-state configurations on the trypanosoma cruzi trans-sialidase free-energy reaction surfaces. | enzymatically catalyzed reactions pass from reactants to products via transition states that are short-lived and potentially characterized from free-energy reaction surfaces. we compute the reaction surface for trypanosoma cruzi trans-sialidase using the free energy from adaptive reaction coordinate forces method. the reaction coordinates are the bonds between the sialic acid and the leaving group (tyr342) and the sialic acid and the nucpleophile (asp59). we are able to track progress of the rea ... | 2015 | 25205134 |
| (1)h, (15)n and (13)c resonance assignments and secondary structure prediction of q4d059, a conserved and kinetoplastid-specific hypothetical protein from trypanosoma cruzi. | trypanosoma cruzi is a human parasite that causes chagas disease, an illness affecting millions of people and without an efficient treatment available. sequencing the pathogen genome has revealed that near half of protein-coding genes correspond to hypothetical proteins of unknown function, increasing the possibilities for novel target discovery. q4d059 is a putative essential hypothetical protein from t. cruzi and it is specific and conserved among the trypanosomatid genomes. here, we report th ... | 2015 | 25023139 |
| chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas: an emerging problem in europe. | chagas disease is a parasitic disease caused by the protozoan trypanosoma cruzi. in endemic areas (south and central america), chagas disease represents a relevant public health issue, and is the most frequent cause of cardiomyopathy. in nonendemic areas, such as europe, chagas disease represents an emerging problem following the establishment of sizeable communities from brazil and bolivia. chagas cardiomyopathy represents the most frequent and serious complication of chronic chagas disease, af ... | 2015 | 25022923 |
| enzymatic decoration of prebiotic galacto-oligosaccharides (vivinal gos) with sialic acid using trypanosoma cruzi trans-sialidase and two bovine sialoglycoconjugates as donor substrates. | decoration of prebiotic galacto-oligosaccharides (gos) with sialic acid yields mixtures of gos and sialylated gos (sia-gos), novel products that are expected to have both prebiotic and antiadhesive functionalities. the recombinantly produced trans-sialidase enzyme from trypanosoma cruzi (tcts), an enzyme with the ability to transfer (α2-3)-linked sialic acid from sialogalactoglycans to asialogalactoglycans, was employed to catalyze this sialylation. as sialic acid acceptor substrates, vivinal go ... | 2015 | 26044147 |
| synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti-trypanosoma cruzi agents. | current chemotherapy drugs for chagas' disease are insufficient due to their limited efficacy; however, anti-trypanosomal agents have recently shown promise. as such, synthetic intermediates of komaroviquinone were evaluated for anti-trypanosomal activity. based on the results, a series of novel quinone derivatives were screened for anti-trypanosomal activity and mammalian cytotoxicity. several quinone derivatives displayed higher antiprotozoal activity against trypanosoma cruzi trypomastigotes ... | 2015 | 26037321 |
| tcpho91 is a contractile vacuole phosphate sodium symporter that regulates phosphate and polyphosphate metabolism in trypanosoma cruzi. | we have identified a phosphate transporter (tcpho91) localized to the bladder of the contractile vacuole complex (cvc) of trypanosoma cruzi, the etiologic agent of chagas disease. tcpho91 has 12 transmembrane domains, an n-terminal regulatory spx (named after syg1, pho81 and xpr1) domain and an anion permease domain. functional expression in xenopus laevis oocytes followed by two-electrode voltage clamp showed that tcpho91 is a low-affinity transporter with a km for pi in the millimolar range, a ... | 2015 | 26031800 |
| trypanothione reductase inhibitors: overview of the action of thioridazine in different stages of chagas disease. | thioridazine (tdz) is a phenothiazine that has been shown to be one of the most potent phenothiazines to inhibit trypanothione reductase irreversibly. trypanothione reductase is an essential enzyme for the survival of trypanosoma cruzi in the host. here, we reviewed the use of this drug for the treatment of t. cruzi experimental infection. in our laboratory, we have studied the effect of tdz for the treatment of mice infected with different strains of t. cruzi and treated in the acute or in the ... | 2015 | 25733492 |
| a kazal-type inhibitor is modulated by trypanosoma cruzi to control microbiota inside the anterior midgut of rhodnius prolixus. | the triatomine insect, rhodnius prolixus, is a vector of trypanosoma cruzi, a protozoan parasite that causes chagas disease. the parasite must overcome immune response and microbiota to develop inside the midgut of triatomines. in this study, we expressed, purified and characterized a kazal-type inhibitor from the midgut of r. prolixus, named rpti, which may be involved in microbiota - t. cruzi interactions. the qpcr showed that the rpti transcript was primarily expressed in tissues from the int ... | 2015 | 25731714 |
| a new era for chagas disease drug discovery? | recent clinical trials investigating treatment of chronic indeterminate chagas disease with two re-purposed azole anti-fungal drugs, posaconazole and ravuconazole, revealed their inferiority to the current standard-of-care benznidazole and highlighted the inadequacy of the existing pre-clinical testing paradigm for this disease. a very limited number of controlled clinical trials for chagas disease have been conducted to date. the selection of these compounds for clinical evaluation relied heavi ... | 2015 | 25727705 |
| geographic variation on biological parameters of meccus picturatus (usinger), 1939 (hemiptera: reduviidae). | the biological parameters related to the life cycles of three populations of meccus picturatus (usinger) (hemiptera: reduviidae), one of the main vectors of trypanosoma cruzi chagas (trypanosomatida: trypanosomatidae), were evaluated. a cohort of each of three populations from geographically isolated localities in western mexico was maintained under similar laboratory conditions, after which all three populations were compared to each other. in each cohort, 50.9 to 72.1% of nymphs completed the ... | 2015 | 26047185 |
| interleukin-17, oxidative stress, and inflammation: role of melatonin during trypanosoma cruzi infection. | although the exact etiology of chagas' disease remains unknown, the inflammatory process and oxidative stress are believed to be the main contributors to the dysfunction and pathogenesis during chronic trypanosoma cruzi infection. our hypothesis is that melatonin administered for 2 months daily could modulate the oxidative stress and the inflammatory response during the chronic infection. flow cytometric analysis of macrophages and antigen-presenting cells (apc), expression of rt1b as well as lf ... | 2015 | 26432539 |
| american trypanosomiasis and associated risk factors in owned dogs from the major city of yucatan, mexico. | the american trypanosomiasis is a zoonosis caused by the protozoa trypanosoma cruzi (t. cruzi). the disease is widely distributed throughout the american continent, affecting a wide range of hosts, including dogs. it is present in the canine population in the state of yucatan, mexico. however, no significant studies in owned dogs have been performed in the metropolitan area of merida. a transversal study was conducted in 370 owned dogs from merida, yucatan, mexico. | 2015 | 26425118 |
| global climate change effects on venezuela's vulnerability to chagas disease is linked to the geographic distribution of five triatomine species. | we analyzed the possible effects of global climate change on the potential geographic distribution in venezuela of five species of triatomines (eratyrus mucronatus (stal, 1859), panstrongylus geniculatus (latreille, 1811), rhodnius prolixus (stål, 1859), rhodnius robustus (larrousse, 1927), and triatoma maculata (erichson, 1848)), vectors of trypanosoma cruzi, the etiological agent of chagas disease. to obtain the future potential geographic distributions, expressed as climatic niche suitability ... | 2015 | 26336258 |
| repellency of the components of the essential oil, citronella, to triatoma rubida, triatoma protracta, and triatoma recurva (hemiptera: reduviidae: triatominae). | the kissing bugs--triatoma rubida (uhler), triatoma protracta (uhler), and triatoma recurva (stal)--are common hematophagous bugs in southeastern arizona and responsible for severe allergic reactions in some individuals who are bitten. they also possess the potential to transmit the blood parasite, trypanosoma cruzi. we previously found the essential oil, citronella, to be an excellent deterrent of feeding of t. rubida on a restrained mouse. in this work, we tested major components--alcohols, al ... | 2015 | 26335480 |
| migration and gene flow among domestic populations of the chagas insect vector triatoma dimidiata (hemiptera: reduviidae) detected by microsatellite loci. | triatoma dimidiata (latreille, 1811) is the most abundant and significant insect vector of the parasite trypanosoma cruzi in central america, and particularly in guatemala. tr. cruzi is the causative agent of chagas disease, and successful disease control requires understanding the geographic distribution and degree of migration of vectors such as t. dimidiata that frequently re-infest houses within months following insecticide application. the population genetic structure of t. dimidiata collec ... | 2015 | 26334816 |
| structural insights into the novel inhibition mechanism of trypanosoma cruzi spermidine synthase. | trypanosoma cruzi causes chagas disease, a severe disease affecting 8-10 million people in latin america. while nifurtimox and benznidazole are used to treat this disease, their efficacy is limited and adverse effects are observed. new therapeutic targets and novel drugs are therefore urgently required. enzymes in the polyamine-trypanothione pathway are promising targets for the treatment of chagas disease. spermidine synthase is a key enzyme in this pathway that catalyzes the transfer of an ami ... | 2015 | 26327378 |
| bestatin induces specific changes in trypanosoma cruzi dipeptide pool. | proteases and peptidases in trypanosoma cruzi are considered potential targets for antichagasic chemotherapy. we monitored changes in low-mass metabolites in t. cruzi epimastigotes treated with bestatin, a dipeptide metalloaminopeptidase inhibitor. after treatment, multiple dipeptides were shown to be increased, confirming in situ inhibition of the leucine aminopeptidase of t. cruzi (laptc) and probably other peptidases. | 2015 | 25712359 |
| 4-nitrobenzaldehyde thiosemicarbazone: a new compound derived from s-(-)-limonene that induces mitochondrial alterations in epimastigotes and trypomastigotes of trypanosoma cruzi. | trypanosoma cruzi is the causative agent of chagas' disease, a parasitic disease that remains a serious health concern with unsatisfactory treatment. drugs that are currently used to treat chagas' disease are partially effective in the acute phase but ineffective in the chronic phase of the disease. the aim of the present study was to evaluate the antitrypanosomal activity and morphological, ultrastructural and biochemical alterations induced by a new molecule, 4-nitrobenzaldehyde thiosemicarbaz ... | 2015 | 25711881 |
| mast cells in the colon of trypanosoma cruzi-infected patients: are they involved in the recruitment, survival and/or activation of eosinophils? | megacolon is frequently observed in patients who develop the digestive form of chagas disease. it is characterized by dilation of the rectum-sigmoid portion and thickening of the colon wall. microscopically, the affected organ presents denervation, which has been considered as consequence of an inflammatory process that begins at the acute phase and persists in the chronic phase of infection. inflammatory infiltrates are composed of lymphocytes, macrophages, natural killer cells, mast cells, and ... | 2015 | 25711147 |
| immunodiagnosis of canine visceral leishmaniasis using mimotope peptides selected from phage displayed combinatorial libraries. | elisa and rifi are currently used for serodiagnosis of canine visceral leishmaniasis (cvl). the accuracy of these tests is controversial in endemic areas where canine infections by trypanosoma cruzi may occur. we evaluated the usefulness of synthetic peptides that were selected through phage display technique in the serodiagnosis of cvl. peptides were chosen based on their ability to bind to iggs purified from infected dogs pooled sera. we selected three phage clones that reacted only with those ... | 2015 | 25710003 |
| nanomedicines against chagas disease: an update on therapeutics, prophylaxis and diagnosis. | chagas disease is a neglected parasitic infection caused by the protozoan trypanosoma cruzi. after a mostly clinically silent acute phase, the disease becomes a lifelong chronic condition that can lead to chronic heart failure and thromboembolic phenomena followed by sudden death. antichagasic treatment is only effective in the acute phase but fails to eradicate the intracellular form of parasites and causes severe toxicity in adults. although conventional oral benznidazol is not a safe and effi ... | 2015 | 25707979 |
| computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir. | in spite of remarkable advances in the knowledge on trypanosoma cruzi biology, no medications to treat chagas disease have been approved in the last 40 years and almost 8 million people remain infected. since the public sector and non-profit organizations play a significant role in the research efforts on chagas disease, it is important to implement research strategies that promote translation of basic research into the clinical practice. recent international public-private initiatives address t ... | 2015 | 25707014 |
| [consensus document for the detection and management of chagas disease in primary health care in a non-endemic areas]. | chagas disease is caused by the protozoan trypanosoma cruzi. although it is commonly transmitted by an insect vector in continental latin-america, in recent decades, due migration, has been diagnosed in other countries such spain, the european country with a largest immigrant population of latin american. for a long time, the patient remains asymptomatic, but some years after this stage, the symptoms can be serious (dilated cardiomyopathy, megacolon, megaesophagus). in addition, detection in pre ... | 2015 | 25704793 |
| synthesis of the o-linked hexasaccharide containing β-d-galp-(1→2)-d-galf in trypanosoma cruzi mucins. differences on sialylation by trans-sialidase of the two constituent hexasaccharides. | the hexasaccharide β-d-galp-(1→2)-[β-d-galp-(1→3)]-β-d-galp-(1→6)-[β-d-galp(1→2)-β-d-galf(1→4)]-d-glcnac (10) and its β-d-galf-(1→2)-β-d-galf containing isomer (7) are the largest carbohydrates in mucins of some strains of trypanosoma cruzi. the terminal β-d-galp units are sites of sialylation by the parasite trans-sialidase. hexasaccharide 10 was chemically synthesized for the first time by a [3+3] nitrilium based convergent approach, using the trichloroacetimidate method of glycosylation. the ... | 2015 | 25703305 |
| interferon-gamma promotes infection of astrocytes by trypanosoma cruzi. | the inflammatory cytokine interferon-gamma (ifnγ) is crucial for immunity against intracellular pathogens such as the protozoan parasite trypanosoma cruzi, the causative agent of chagas disease (cd). ifnγ is a pleiotropic cytokine which regulates activation of immune and non-immune cells; however, the effect of ifnγ in the central nervous system (cns) and astrocytes during cd is unknown. here we show that parasite persists in the cns of c3h/he mice chronically infected with the colombian t. cruz ... | 2015 | 25695249 |
| human leucocyte antigen-g (hla-g) and its murine functional homolog qa2 in the trypanosoma cruzi infection. | genetic susceptibility factors, parasite strain, and an adequate modulation of the immune system seem to be crucial for disease progression after trypanosoma cruzi infection. hla-g and its murine functional homolog qa2 have well-recognized immunomodulatory properties. we evaluated the hla-g 3' untranslated region (3'utr) polymorphic sites (associated with mrna stability and target for microrna binding) and hla-g tissue expression (heart, colon, and esophagus) in patients presenting chagas diseas ... | 2015 | 25688175 |
| the impact of climate change on the geographical distribution of two vectors of chagas disease: implications for the force of infection. | chagas disease, caused by the parasite trypanosoma cruzi, is the most important vector-borne disease in latin america. the vectors are insects belonging to the triatominae (hemiptera, reduviidae), and are widely distributed in the americas. here, we assess the implications of climatic projections for 2050 on the geographical footprint of two of the main chagas disease vectors: rhodnius prolixus (tropical species) and triatoma infestans (temperate species). we estimated the epidemiological implic ... | 2015 | 25688019 |
| evidence of meaningful levels of trypanosoma cruzi in platelet concentrates from seropositive blood donors. | according to the reported cases of transfusion-acquired trypanosoma cruzi infection, the risk of t. cruzi transfusion transmission appears to be higher with platelet (plt) products than with other blood components. the aim of this study was to investigate by quantitative real-time polymerase chain reaction (qpcr) the parasitic load detected in leukoreduced plasma and plt concentrates collected by apheresis from seropositive t. cruzi blood donors and compare them with peripheral whole blood (wb). | 2015 | 25683267 |
| trypanosoma cruzi infection is a potent risk factor for non-alcoholic steatohepatitis enhancing local and systemic inflammation associated with strong oxidative stress and metabolic disorders. | the immune mechanisms underlying experimental non-alcoholic steatohepatitis (nash), and more interestingly, the effect of t. cruzi chronic infection on the pathogenesis of this metabolic disorder are not completely understood. | 2015 | 25668433 |
| a national survey to determine prevalence of trypanosoma cruzi infection among pregnant women in ecuador. | a nationwide survey was conducted to obtain an estimate of chagas disease prevalence among pregnant women in ecuador. as part of a national probability sample, 5,420 women seeking care for delivery or miscarriage at 15 healthcare facilities were recruited into the study. a small minority of participants reported knowing about chagas disease or recognized the vector. a national seroprevalence of 0.1% (95% confidence interval [95% ci] = 0.0-0.2%) was found; cases were concentrated in the coastal r ... | 2015 | 25667052 |
| abcg-like transporter of trypanosoma cruzi involved in benznidazole resistance: gene polymorphisms disclose inter-strain intragenic recombination in hybrid isolates. | benznidazole (bz) is one of the two drugs for chagas disease treatment. in a previous study we showed that the trypanosoma cruzi abcg-like transporter gene, named tcabcg1, is over-expressed in parasite strains naturally resistant to bz and that the gene of tci bz-resistant strains exhibited several single nucleotide polymorphisms (snps) as compared to the gene of cl brener bz-susceptible strain. here we report the sequence of tcabcg1 gene of fourteen t. cruzi strains, with diverse degrees of bz ... | 2015 | 25660041 |
| a membrane-bound eif2 alpha kinase located in endosomes is regulated by heme and controls differentiation and ros levels in trypanosoma cruzi. | translation initiation has been described as a key step for the control of growth and differentiation of several protozoan parasites in response to environmental changes. this occurs by the activation of protein kinases that phosphorylate the alpha subunit of the translation initiation factor 2 (eif2α), which decreases translation, and in higher eukaryotes favors the expression of stress remedial response genes. however, very little is known about the signals that activate eif2α kinases in proto ... | 2015 | 25658109 |
| volatile compound diversity and conserved alarm behaviour in triatoma dimidiata. | triatoma dimidiata (latreille) is a key vector complex of trypanosoma cruzi, etiologic agent of chagas disease, as it spans north, central, and south america. although morphological and genetic studies clearly indicate existence of at least five clades within the species, there has been no robust or systematic revision, or appropriate nomenclature change for species within the complex. three of the clades (haplogroups) are distributed in mexico, and recent evidence attests to dispersal of clades ... | 2015 | 25656170 |
| evidence of reversible bradycardia and arrhythmias caused by immunogenic proteins secreted by t. cruzi in isolated rat hearts. | chagas cardiomyopathy, caused by the protozoan trypanosoma cruzi, is characterized by alterations in intracellular ion, heart failure and arrhythmias. arrhythmias have been related to sudden death, even in asymptomatic patients, and their molecular mechanisms have not been fully elucidated. | 2015 | 25647069 |
| altering the motility of trypanosoma cruzi with rabbit polyclonal anti-peptide antibodies reduces infection to susceptible mammalian cells. | trypanosoma cruzi's trypomastigotes are highly active and their incessant motility seems to be important for mammalian host cell infection. the kinetoplastid membrane protein-11 (kmp-11) is a protein expressed in all parasite stages, which induces a cellular and humoral immune response in the infected host, and is hypothesized to participate in the parasite's motility. an n-terminal peptide from kmp-11, termed k1 or tctle, induced polyclonal antibodies that inhibit parasitic invasion of vero cel ... | 2015 | 25633439 |
| deficiency of antigen-specific b cells results in decreased trypanosoma cruzi systemic but not mucosal immunity due to cd8 t cell exhaustion. | vaccines against mucosally invasive, intracellular pathogens must induce a myriad of immune responses to provide optimal mucosal and systemic protection, including cd4(+) t cells, cd8(+) t cells, and ab-producing b cells. in general, cd4(+) t cells are known to provide important helper functions for both cd8(+) t cell and b cell responses. however, the relative importance of cd4(+) t cells, cd8(+) t cells, and b cells for mucosal protection is less clearly defined. we have studied these question ... | 2015 | 25595788 |
| a human type 5 adenovirus-based trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. | chagas disease (cd), caused by the protozoan trypanosoma cruzi, is a prototypical neglected tropical disease. specific immunity promotes acute phase survival. nevertheless, one-third of cd patients develop chronic chagasic cardiomyopathy (ccc) associated with parasite persistence and immunological unbalance. currently, the therapeutic management of patients only mitigates ccc symptoms. therefore, a vaccine arises as an alternative to stimulate protective immunity and thereby prevent, delay progr ... | 2015 | 25617628 |
| automated high-content assay for compounds selectively toxic to trypanosoma cruzi in a myoblastic cell line. | chagas disease, caused by the protozoan parasite trypanosoma cruzi, represents a very important public health problem in latin america where it is endemic. although mostly asymptomatic at its initial stage, after the disease becomes chronic, about a third of the infected patients progress to a potentially fatal outcome due to severe damage of heart and gut tissues. there is an urgent need for new drugs against chagas disease since there are only two drugs available, benznidazole and nifurtimox, ... | 2015 | 25615687 |
| the brighter (and evolutionarily older) face of the metabolic syndrome: evidence from trypanosoma cruzi infection in cd-1 mice. | infection with trypanosoma cruzi, the protozoan parasite that causes chagas disease, results in chronic infection that leads to cardiomyopathy with increased mortality and morbidity in endemic regions. in a companion study, our group found that a high-fat diet (hfd) protected mice from t. cruzi-induced myocardial damage and significantly reduced post-infection mortality during acute t. cruzi infection. | 2015 | 25613819 |
| immunoregulatory actions of melatonin and zinc during chronic trypanosoma cruzi infection. | after one century of the discovery of chagas' disease and the development of an efficient drug with amplitude of actions both in the acute and chronic phase is still a challenge. alternative immune modulators have been exhaustively used. for that purpose, melatonin and zinc were administered during chronic trypanosoma cruzi-infected wistar rats and several endpoints were assessed. melatonin has a remarkable functional versatility, being associated with important antioxidant, anti-inflammatory, a ... | 2015 | 25611919 |
| eco-bio-social research on community-based approaches for chagas disease vector control in latin america. | this article provides an overview of three research projects which designed and implemented innovative interventions for chagas disease vector control in bolivia, guatemala and mexico. the research initiative was based on sound principles of community-based ecosystem management (ecohealth), integrated vector management, and interdisciplinary analysis. the initial situational analysis achieved a better understanding of ecological, biological and social determinants of domestic infestation. the ke ... | 2015 | 25604759 |
| immunomodulatory properties and anti-apoptotic effects of zinc and melatonin in an experimental model of chronic chagas disease. | the immunomodulatory effects of melatonin and zinc during chronic experimental chagas' disease were studied. early and late apoptosis by annexin v-propidium iodide staining were evaluated. the expression of cd28, cd80, cd86, cd45ra and cd4(+)t and cd8(+)t cells were also evaluated by flow cytometry analysis. the combination of zinc and melatonin notably reduced the apoptotic ratios of splenic cells in the infected and treated animals when compared to untreated rats, during early and late stages ... | 2015 | 25604665 |
| follow-up of an asymptomatic chagas disease population of children after treatment with nifurtimox (lampit) in a sylvatic endemic transmission area of colombia. | chagas disease is an anthropozoonosis caused by trypanosoma cruzi. two drugs are currently used for the etiological treatment of the disease: nifurtimox (lampit) and benznidazole. this study presents a quasi-experimental trial (non-control group) of sixty-two patients who were treated for chagas disease with nifurtimox (lampit), and were then followed for 30 months post-treatment. the safety of nifurtimox (lampit) for chagas disease in this group of children primarily between 4 and 19 years old ... | 2015 | 25723465 |
| antigen targeting to dendritic cells allows the identification of a cd4 t-cell epitope within an immunodominant trypanosoma cruzi antigen. | targeting antigens to dendritic cells (dcs) by using hybrid monoclonal antibodies (mabs) directed against dc receptors is known to improve activation and support long-lasting t cell responses. in the present work, we used the mab αdec205 fused to the trypanosoma cruzi amastigote surface protein 2 (asp-2) to identify a region of this protein recognized by specific t cells. the hybrid αdec-asp2 mab was successfully generated and preserved its ability to bind the dec205 receptor. immunization of ba ... | 2015 | 25679777 |
| detection of trypanosoma cruzi dna in blood by pcr is associated with chagas cardiomyopathy and disease severity. | the significance of detection of trypanosoma cruzi dna in blood of antibody-positive patients for risk of development of chagas heart disease is not well established. the objective of this study was to compare detection of t. cruzi dna with known clinical and laboratory markers of chagas cardiomyopathy (cc) severity. | 2015 | 25678239 |
| geographical distribution of trypanosoma cruzi in triatomine vectors in the state of mato grosso do sul, brazil. | this work presents the initial findings of a molecular epidemiological investigation of trypanosoma cruzi in triatomine insects in state of mato grosso do sul. | 2015 | 25626654 |
| ecoepidemiology and biology of eratyrus mucronatus stål, 1859 (hemiptera: reduviidae: triatominae), a sylvatic vector of chagas disease in the brazilian amazon. | eratyrus mucronatus stål, 1859 is a wild triatomine vector of trypanosoma cruzi chagas, 1909. however, little is known regarding the biology and ecoepidemiology of this triatomine in the brazilian amazon. the present study describes the biology of e. mucronatus grown under laboratory conditions and the epidemiological aspects of its natural breeding sites. | 2015 | 25626651 |
| experimental benznidazole treatment of trypanosoma cruzi ii strains isolated from children of the jequitinhonha valley, minas gerais, brazil, with chagas disease. | trypanosoma cruzi strains from distinct geographic areas show differences in drug resistance and association between parasites genetic and treatment response has been observed. considering that benznidazole (bz) can reduce the parasite burden and tissues damage, even in not cured animals and individuals, the goal is to assess the drug response to bz of t. cruzi ii strains isolated from children of the jequitinhonha valley, state of minas gerais, brazil, before treatment. mice infected and treate ... | 2015 | 25626455 |
| efficacy of a trans-sialidase-iscomatrix subunit vaccine candidate to protect against experimental chagas disease. | recombinant protein vaccines are safe but elicit low immunological responses. the new generation of adjuvants is currently reversing this situation. here, a new antigen-adjuvant combination for protection against experimental chagas disease was assessed. the antigen used in the formulation was a glycosylated mutant inactive trans-sialidase (mts) that was previously proven to be highly protective against trypanosoma cruzi infection; here, we show that it can be produced in large quantities and hi ... | 2015 | 25625671 |
| mapping antigenic motifs in the trypomastigote small surface antigen from trypanosoma cruzi. | the trypomastigote small surface antigen (tssa) is a mucin-like molecule from trypanosoma cruzi, the etiological agent of chagas disease, which displays amino acid polymorphisms in parasite isolates. tssa expression is restricted to the surface of infective cell-derived trypomastigotes, where it functions as an adhesin and engages surface receptors on the host cell as a prerequisite for parasite internalization. previous results have established tssa-cl, the isoform encoded by the cl brener clon ... | 2015 | 25589551 |
| trypanosoma cruzi infection in triatoma sordida before and after community-wide residual insecticide spraying in the argentinean chaco. | triatoma sordida is a secondary vector of trypanosoma cruzi in the gran chaco and cerrado eco-regions where it frequently infests peridomestic and domestic habitats. in a well-defined area of the humid argentine chaco, very few t. sordida were found infected when examined by optical microscopic examination (om). in order to further assess the role of t. sordida and the relative magnitude of subpatent bug infections, we examined the insects for t. cruzi infection, parasite discrete typing units ( ... | 2015 | 25579426 |
| [trypanosoma cruzi in an immunocompromised patient. reactivation of chagas disease in a resident of la rioja city, argentina]. | 2015 | 25576424 | |
| trypanosoma cruzi: biotherapy made from trypomastigote modulates the inflammatory response. | this study evaluates the effect of trypanosoma cruzi biotherapy 17dh (biot) on mice of different ages, infected with the protozoa concerned. | 2015 | 25576271 |
| host-seeking behavior and dispersal of triatoma infestans, a vector of chagas disease, under semi-field conditions. | chagas disease affects millions of people in latin america. the control of this vector-borne disease focuses on halting transmission by reducing or eliminating insect vector populations. most transmission of trypanosoma cruzi, the causative agent of chagas disease, involves insects living within or very close to households and feeding mostly on domestic animals. as animal hosts can be intermittently present it is important to understand how host availability can modify transmission risk to human ... | 2015 | 25569228 |
| low frequency of circulating cd8+ t stem cell memory cells in chronic chagasic patients with severe forms of the disease. | cd8+ t cells have been shown to play a crucial role in trypanosoma cruzi infection. memory cd8+ t cells can be categorised based on their distinct differentiation stages and functional activities as follows: stem cell memory (tscm), central memory (tcm), transitional memory (ttm), effector memory (tem) and terminal effector (tte) cells. currently, the immune mechanisms that control t. cruzi in the chronic phase of the infection are unknown. | 2015 | 25569149 |